Swarmer (SWMR) registers 3M shares for Lucid liquidity line
Swarmer, Inc. filed a prospectus to register up to 3,000,000 shares of its common stock for resale by Lucid Capital Markets, LLC (the "Selling Stockholder") under a June 10, 2026 Purchase Agreement (the "Lucid Liquidity Line"). The company is not selling shares under this prospectus; proceeds from resales by the Selling Stockholder will go to Lucid. The Company may, at its option after the registration is effective, issue and sell shares to Lucid under the Purchase Agreement and could receive up to approximately $181 million in aggregate gross proceeds based on an assumed price of $60.32 per share, subject to the Purchase Agreement terms and conditions. The Purchase Agreement limits the Selling Stockholder’s beneficial ownership to 4.99% and contains an Exchange Cap of 19.99%; the facility lasts up to 24 months after Commencement and contains customary conditions for purchases, pricing based on 98% of VWAP, and thresholds that govern intraday and regular purchases.
Positive
- None.
Negative
- None.
Insights
Registration permits resale of up to 3,000,000 shares under a liquidity line with purchaser protections.
The prospectus registers 3,000,000 shares for resale by Lucid under a Purchase Agreement that gives the company discretion to direct purchases over a 24-month term after Commencement. Purchases are priced at 98% of VWAP over specified valuation periods and are subject to minimum price and volume thresholds.
The transaction is treated as a conflict-of-interest offering under FINRA Rule 5121, so a qualified independent underwriter (Seaport) was retained. Key limits include a 4.99% beneficial ownership cap per holder and an Exchange Cap of 19.99%; timing and cash-flow to the company depend on the company electing to issue shares to Lucid.
Key Figures
Key Terms
Lucid Liquidity Line financial
VWAP market
Beneficial Ownership Limitation regulatory
Exchange Cap regulatory
Offering Details
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the SWMR prospectus register?
Will Swarmer receive proceeds from the resales under this prospectus?
How much could Swarmer receive if it issues shares to Lucid?
What pricing mechanism governs purchases by Lucid under the Purchase Agreement?
What ownership and issuance caps apply to the Lucid Liquidity Line?
| |
ABOUT THIS PROSPECTUS
|
| | | | ii | | |
| |
MARKET AND INDUSTRY DATA
|
| | | | ii | | |
| |
TRADEMARKS
|
| | | | ii | | |
| |
PROSPECTUS SUMMARY
|
| | | | 1 | | |
| |
THE OFFERING
|
| | | | 11 | | |
| |
SUMMARY FINANCIAL DATA
|
| | | | 14 | | |
| |
RISK FACTORS
|
| | | | 16 | | |
| |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 48 | | |
| |
LUCID LIQUIDITY LINE
|
| | | | 50 | | |
| |
USE OF PROCEEDS
|
| | | | 60 | | |
| |
SELLING STOCKHOLDER
|
| | | | 61 | | |
| |
DIVIDEND POLICY
|
| | | | 63 | | |
| |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
| | | | 64 | | |
| |
BUSINESS
|
| | | | 75 | | |
| |
MANAGEMENT
|
| | | | 86 | | |
| |
EXECUTIVE AND DIRECTOR COMPENSATION
|
| | | | 94 | | |
| |
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
|
| | | | 103 | | |
| |
PRINCIPAL STOCKHOLDERS
|
| | | | 107 | | |
| |
DESCRIPTION OF CAPITAL STOCK
|
| | | | 109 | | |
| |
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
|
| | | | 115 | | |
| |
PLAN OF DISTRIBUTION (CONFLICT OF INTEREST)
|
| | | | 119 | | |
| |
LEGAL MATTERS
|
| | | | 122 | | |
| |
EXPERTS
|
| | | | 122 | | |
| |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 122 | | |
| |
INDEX TO FINANCIAL STATEMENTS
|
| | | | F-1 | | |
offering
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Revenue
|
| | | $ | 309,920 | | | | | $ | 329,410 | | |
|
Cost of revenue
|
| | | | 182,163 | | | | | | 187,848 | | |
|
Gross margin
|
| | | | 127,757 | | | | | | 141,562 | | |
| Operating expenses: | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 2,665,004 | | | | | | 368,795 | | |
|
Research and development
|
| | | | 2,578,860 | | | | | | 1,011,498 | | |
|
Total operating expenses
|
| | | | 5,243,864 | | | | | | 1,380,293 | | |
|
Loss from operations
|
| | | | (5,116,107) | | | | | | (1,238,731) | | |
| Other income (expense): | | | | | | | | | | | | | |
|
Change in fair value of SAFE liability
|
| | | | (3,493,431) | | | | | | (829,700) | | |
|
Other income
|
| | | | 80,275 | | | | | | 524 | | |
|
Loss before income taxes
|
| | | | (8,529,263) | | | | | | (2,067,907) | | |
|
Income tax expense
|
| | | | — | | | | | | (1,735) | | |
|
Net loss
|
| | | $ | (8,529,263) | | | | | $ | (2,069,642) | | |
| Per share information: | | | | | | | | | | | | | |
|
Net loss per share of common stock, basic and diluted(1)
|
| | | $ | (2.46) | | | | | $ | (2.68) | | |
|
Weighted average common shares outstanding, basic and diluted(1)
|
| | | | 3,461,565 | | | | | $ | 772,351 | | |
|
Pro forma net loss per share attributable to common stockholders, basic and diluted(2)
|
| | | $ | (0.99) | | | | | | | | |
|
Pro forma weighted-average shares outstanding, basic and diluted, basic and diluted(2)
|
| | | | 5,097,353 | | | | | | | | |
| | | |
Three Months Ended March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
|
Revenue
|
| | | $ | 20,325 | | | | | $ | 110,704 | | |
|
Cost of revenue
|
| | | | 39,924 | | | | | | 45,542 | | |
|
Gross margin
|
| | | | (19,599) | | | | | | 65,162 | | |
| Operating expenses: | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 3,004,879 | | | | | | 255,281 | | |
|
Research and development
|
| | | | 1,486,082 | | | | | | 522,198 | | |
|
Total operating expenses
|
| | | | 4,490,961 | | | | | | 777,479 | | |
|
Loss from operations
|
| | | | (4,510,560) | | | | | | (712,317) | | |
| Other income: | | | | | | | | | | | | | |
|
Other income
|
| | | | 51,725 | | | | | | 18,340 | | |
|
Loss before income taxes
|
| | | | (4,458,835) | | | | | | (693,977) | | |
|
Income tax expense
|
| | | | — | | | | | | — | | |
|
Net loss
|
| | | $ | (4,458,835) | | | | | $ | (693,977) | | |
| Per share information: | | | | | | | | | | | | | |
|
Net loss per share of common stock, basic and diluted
|
| | | $ | (0.28) | | | | | $ | (0.25) | | |
|
Weighted-average shares of common stock outstanding, basic and diluted
|
| | | | 16,064,920 | | | | | | 2,725,467 | | |
| | | |
As of March 31, 2026
(unaudited) |
| ||||||||||||
| | | |
Actual
|
| | | | |
Pro Forma as
Adjusted(2) |
| ||||||
| Balance Sheet Data: | | | | | | | | | | | | | | | | |
|
Cash and cash equivalents
|
| | | $ | 23,472,156 | | | | | | | | $ | 204,282,156 | | |
|
Working capital(1)
|
| | | | 22,918,566 | | | | | | | | | 203,728,566 | | |
|
Total assets
|
| | | | 24,927,110 | | | | | | | | | 205,737,110 | | |
|
Total liabilities
|
| | | | 1,406,519 | | | | | | | | | 1,406,519 | | |
|
Total stockholders’ equity
|
| | | | 23,520,591 | | | | | | | | | 204,330,591 | | |
| |
Assumed
Average Purchase Price Per Share |
| |
Number of Registered
Shares to be Issued if Full Purchase(1) |
| |
Percentage of
Outstanding Shares After Giving Effect to the Issuance to the Selling Stockholder(2) |
| |
Gross Proceeds from the
Sale of Shares to the Selling Stockholder Under the Purchase Agreement |
| |||||||||
| |
$50.32
|
| | | | 3,000,000 | | | | | | 21.1% | | | | | $ | 150,960,000 | | |
| |
$55.32
|
| | | | 3,000,000 | | | | | | 21.1% | | | | | $ | 165,960,000 | | |
| |
$60.32(3)
|
| | | | 3,000,000 | | | | | | 21.1% | | | | | $ | 180,960,000 | | |
| |
$65.32
|
| | | | 3,000,000 | | | | | | 21.1% | | | | | $ | 195,960,000 | | |
| |
$70.32
|
| | | | 3,000,000 | | | | | | 21.1% | | | | | $ | 210,960,000 | | |
| | | |
Number of Shares of
Common Stock Beneficially Owned Prior to Offering |
| |
Maximum
Number of Shares of Common Stock to be Offered Pursuant to this Prospectus |
| |
Number of Shares of
Common Stock Beneficially Owned After Offering(3) |
| |||||||||||||||||||||
|
Name of Selling Stockholder
|
| |
Number(1)
|
| |
Percent(2)
|
| |
Number(1)
|
| |
Percent
|
| ||||||||||||||||||
|
Lucid / Lucid Capital Markets, LLC(4)
|
| | | | 0 | | | | | | * | | | | | | 3,000,000 | | | | | | 0 | | | | | | * | | |
| | | |
Three Months Ended March 31,
|
| | | | ||||||||||||
| | | |
2026
|
| |
2025
|
| |
$ Change
|
| |||||||||
|
Revenue
|
| | | $ | 20,325 | | | | | $ | 110,704 | | | | | $ | (90,379) | | |
|
Cost of revenue
|
| | | | 39,924 | | | | | | 45,542 | | | | | | (5,618) | | |
|
Gross margin
|
| | | | (19,599) | | | | | | 65,162 | | | | | | (84,761) | | |
| Operating expenses: | | | | | | | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 3,004,879 | | | | | | 255,281 | | | | | | 2,749,598 | | |
|
Research and development
|
| | | | 1,486,082 | | | | | | 522,198 | | | | | | 963,884 | | |
|
Total operating expenses
|
| | | | 4,490,961 | | | | | | 777,479 | | | | | | 3,713,482 | | |
|
Loss from operations
|
| | | | (4,510,560) | | | | | | (712,317) | | | | | | (3,798,243) | | |
| Other income: | | | | | | | | | | | | | | | | | | | |
|
Other income
|
| | | | 51,725 | | | | | | 18,340 | | | | | | 33,385 | | |
|
Loss before income taxes
|
| | | | (4,458,835) | | | | | | (693,977) | | | | | | (3,764,858) | | |
|
Income tax expense
|
| | | | — | | | | | | — | | | | | | — | | |
|
Net loss
|
| | | $ | (4,458,835) | | | | | $ | (693,977) | | | | | $ | (3,764,858) | | |
| | | |
Years Ended December 31,
|
| | | | ||||||||||||
| | | |
2025
|
| |
2024
|
| |
$ Change
|
| |||||||||
|
Revenue
|
| | | $ | 309,920 | | | | | $ | 329,410 | | | | | $ | (19,490) | | |
|
Cost of revenue
|
| | | | 182,163 | | | | | | 187,848 | | | | | | (5,685) | | |
|
Gross margin
|
| | | | 127,757 | | | | | | 141,562 | | | | | | (13,805) | | |
| Operating expenses: | | | | | | | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 2,665,004 | | | | | | 368,795 | | | | | | 2,296,209 | | |
|
Research and development
|
| | | | 2,578,860 | | | | | | 1,011,498 | | | | | | 1,567,362 | | |
|
Total operating expenses
|
| | | | 5,243,864 | | | | | | 1,380,293 | | | | | | 3,863,571 | | |
|
Loss from operations
|
| | | | (5,116,107) | | | | | | (1,238,731) | | | | | | (3,877,376) | | |
| Other income (expense): | | | | | | | | | | | | | | | | | | | |
|
Change in fair value of SAFE liability
|
| | | | (3,493,431) | | | | | | (829,700) | | | | | | (2,663,731) | | |
|
Other income
|
| | | | 80,275 | | | | | | 524 | | | | | | 79,751 | | |
|
Loss before income taxes
|
| | | | (8,529,263) | | | | | | (2,067,907) | | | | | | (6,461,356) | | |
|
Income tax expense
|
| | | | — | | | | | | (1,735) | | | | | | 1,735 | | |
|
Net loss
|
| | | $ | (8,529,263) | | | | | $ | (2,069,642) | | | | | $ | (6,459,621) | | |
| | | |
Three Months Ended March 31,
|
| |
Years Ended December 31,
|
| ||||||||||||||||||
| | | |
2026
|
| |
2025
|
| |
2025
|
| |
2024
|
| ||||||||||||
|
Cash used in operating activities
|
| | | $ | (4,277,048) | | | | | $ | (681,797) | | | | | $ | (4,622,351) | | | | | $ | (1,046,126) | | |
|
Cash used in investing activities
|
| | | | (124,331) | | | | | | — | | | | | | (246,993) | | | | | | (8,956) | | |
|
Cash provided by financing activities
|
| | | | 18,616,305 | | | | | | — | | | | | | 12,078,091 | | | | | | 3,011,513 | | |
|
Effect of exchange rate changes on cash
|
| | | | (26,336) | | | | | | (1,785) | | | | | | (6,267) | | | | | | (167) | | |
|
Net increase in cash and cash equivalents
|
| | | $ | 14,188,590 | | | | | $ | (683,582) | | | | | $ | 7,202,480 | | | | | $ | 1,956,264 | | |
|
Name
|
| |
Age
|
| |
Position
|
|
| Executive Officers: | | | | | | | |
| Serhii Kupriienko | | |
40
|
| | Chief Executive Officer (Global) and Director | |
| Alexander Fink | | |
41
|
| | Chief Executive Officer (U.S.), President and Director | |
| Brooks Ensign | | |
60
|
| | Chief Financial Officer and Treasurer | |
| Jennifer DeTrani | | |
52
|
| | Chief Legal Officer, General Counsel and Secretary | |
| Non-Employee Directors: | | | | | | | |
| Erik Prince | | |
56
|
| | Chairman | |
| Edward Antoian | | |
70
|
| | Director | |
| Amir Frenkel | | |
49
|
| | Director | |
| Derek Reisfield | | |
63
|
| | Director | |
| Philip Wagenheim | | |
55
|
| | Director | |
| Justin Zeefe | | |
48
|
| | Director | |
|
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Option
Awards ($)(1) |
| |
Non-Equity
Incentive Plan Compensation ($)(2) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||||||||
|
Serhii Kupriienko(3)(4)
Chief Executive Officer (Global) |
| | | | 2025 | | | | | | 166,985 | | | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | 166,985 | | |
| | | | 2024 | | | | | | 92,243 | | | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | 92,243 | | | ||
|
Alexander Fink(3)(5)
Chief Executive Officer (U.S.) and President, and former Chief Financial Officer and Treasurer |
| | | | 2025 | | | | | | 121,897 | | | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | 121,897 | | |
| | | | 2024 | | | | | | 16,500 | | | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | 16,500 | | | ||
| | | |
Option
|
| |||||||||||||||||||||
|
Name
|
| |
Unexercised
Options (#) Exercisable |
| |
Unexercised
Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
|
Serhii Kupriienko
|
| | | | 3,292,275 | | | | | | 2,351,625 | | | | | $ | 0.00001 | | | | | | 09/14/2033 | | |
|
Alexander Fink(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Position
|
| |
Retainer
|
| |||
|
Board Member
|
| | | $ | 40,000 | | |
|
Board Chairperson
|
| | | $ | — | | |
|
Audit Committee Chair
|
| | | $ | 15,000 | | |
|
Compensation Committee Chair
|
| | | $ | 10,000 | | |
|
Nominating and Corporate Governance Committee Chair
|
| | | $ | 10,000 | | |
|
Audit Committee Member
|
| | | $ | 7,500 | | |
|
Compensation Committee Member
|
| | | $ | 5,000 | | |
|
Nominating and Corporate Governance Committee Member
|
| | | $ | 5,000 | | |
|
Name
|
| |
Shares of
Series A-1 Convertible Preferred Stock Purchased |
| |
Aggregate
Purchase Price |
| ||||||
|
Theseus Capital Partners, LLC(1)
|
| | | | 597,980 | | | | | $ | 3,749,992 | | |
|
RG.AI Technologies, Inc.
|
| | | | 194,805 | | | | | $ | 1,221,642 | | |
|
D3 Fund, LP
|
| | | | 139,939 | | | | | $ | 877,575 | | |
|
Green Flag Fund I, L.P.(2)
|
| | | | 74,380 | | | | | $ | 466,444 | | |
|
Name
|
| |
Shares of
Series A-2 Convertible Preferred Stock Received upon Conversion of SAFEs |
| |||
|
D3 Fund, LP
|
| | | | 223,336 | | |
|
Name
|
| |
Shares of
Series A-4 Convertible Preferred Stock Received upon Conversion of SAFEs |
| |||
|
RG.AI Technologies, Inc
|
| | | | 501,166 | | |
|
D3 Fund, LP
|
| | | | 136,681 | | |
|
Green Flag Fund I, L.P.
|
| | | | 191,354 | | |
|
Radius Fund I, L.P.
|
| | | | 341,704 | | |
| | | |
Shares
Beneficially Owned |
| |
Percentage of Shares
Beneficially Owned |
| ||||||||||||
|
Name and Address of Beneficial Owner(1)
|
| |
Before
Offering |
| |
After
Offering |
| ||||||||||||
| Greater than 5% Stockholders: | | | | | | | | | | | | | | | | | | | |
|
Theseus Capital Partners, LLC(2)
|
| | | | 1,124,981 | | | | | | 10.0% | | | | | | 7.9% | | |
|
D3 Fund, LP(3)
|
| | | | 940,569 | | | | | | 8.4% | | | | | | 6.6% | | |
|
RG.AI Technologies, Inc.(4)
|
| | | | 1,309,331 | | | | | | 11.7% | | | | | | 9.2% | | |
|
Radius Fund I, L.P.(5)
|
| | | | 642,848 | | | | | | 5.7% | | | | | | 4.5% | | |
| Named Executive Officers and Directors: | | | | | | | | | | | | | | | | | | | |
|
Serhii Kupriienko(6)
|
| | | | 3,922,600 | | | | | | 25.9% | | | | | | 21.6% | | |
|
Alexander Fink(7)
|
| | | | 1,435,974 | | | | | | 12.8% | | | | | | 10.1% | | |
|
Erik Prince(8)
|
| | | | — | | | | | | — | | | | | | — | | |
|
Philip Wagenheim(9)
|
| | | | 1,124,981 | | | | | | 10.0% | | | | | | 7.9% | | |
|
Justin Zeefe(10)
|
| | | | 499,927 | | | | | | 4.5% | | | | | | 3.5% | | |
|
Edward Antoian(11)
|
| | | | — | | | | | | — | | | | | | — | | |
|
Amir Frenkel(12)
|
| | | | — | | | | | | — | | | | | | — | | |
|
Derek Reisfield(13)
|
| | | | — | | | | | | — | | | | | | — | | |
|
All current executive officers and directors as a group (10 persons)(14)
|
| | | | 6,983,482 | | | | | | 46.1% | | | | | | 38.5% | | |
| | | |
Page
|
| |||
| Audited Financial Statements | | | | | | | |
|
Report of Independent Registered Public Accounting Firm (PCAOB ID: 199)
|
| | | | F-2 | | |
|
Consolidated Balance Sheets at December 31, 2025 and 2024
|
| | | | F-3 | | |
|
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024
|
| | | | F-4 | | |
|
Consolidated Statements of Convertible Preferred Stock and Shareholders’ Deficit for the years ended December 31, 2025 and 2024
|
| | | | F-5 | | |
|
Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024
|
| | | | F-6 | | |
|
Notes to the Consolidated Financial Statements
|
| | | | F-7 | | |
| | Unaudited Condensed Consolidated Interim Financial Statements | | | | | | | |
| |
Condensed Consolidated Balance Sheets at March 31, 2026 and December 31, 2025
|
| | | | F-26 | | |
| |
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025
|
| | | | F-27 | | |
| |
Condensed Consolidated Statements of Convertible Preferred Stock and Shareholders’ Equity (Deficit) for the three months ended March 31, 2026 and 2025
|
| | | | F-28 | | |
| |
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and
2025 |
| | | | F-29 | | |
| |
Notes to the Unaudited Condensed Consolidated Financial Statements
|
| | | | F-30 | | |
Swarmer, Inc
February 2, 2026, except for Note 14 as to which the date is February 19, 2026
| | | |
December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
| Assets | | | | | | | | | | | | | |
| Current assets: | | | | | | | | | | | | | |
|
Cash and cash equivalents
|
| | | $ | 9,283,566 | | | | | $ | 2,081,086 | | |
|
Unbilled revenue
|
| | | | — | | | | | | 11,939 | | |
|
Prepaid expenses and other current assets
|
| | | | 115,473 | | | | | | 49,477 | | |
|
Total current assets
|
| | | | 9,399,039 | | | | | | 2,142,502 | | |
|
Property and equipment, net
|
| | | | 227,908 | | | | | | 5,401 | | |
|
Operating lease right-of-use asset
|
| | | | 131,184 | | | | | | — | | |
|
Deferred offering costs
|
| | | | 471,719 | | | | | | — | | |
|
Other assets
|
| | | | 106,830 | | | | | | — | | |
|
Total assets
|
| | | $ | 10,336,680 | | | | | $ | 2,147,903 | | |
| Liabilities, convertible preferred stock and shareholders’ deficit | | | | | | | | | | | | | |
| Current liabilities: | | | | | | | | | | | | | |
|
Accounts payable
|
| | | $ | 223,236 | | | | | $ | 974 | | |
|
Accrued expenses and other current liabilities
|
| | | | 680,782 | | | | | | 203,605 | | |
|
Grant advance
|
| | | | 189,200 | | | | | | 47,540 | | |
|
Deferred revenue
|
| | | | 23,272 | | | | | | — | | |
|
Operating lease liability – current
|
| | | | 70,703 | | | | | | — | | |
|
Total current liabilities
|
| | | | 1,187,193 | | | | | | 252,119 | | |
|
Operating lease liability – non-current
|
| | | | 76,273 | | | | | | — | | |
|
SAFE liability, fair value
|
| | | | — | | | | | | 3,965,000 | | |
|
Total liabilities
|
| | | | 1,263,466 | | | | | | 4,217,119 | | |
| Convertible preferred stock, par value $0.00001 per share: | | | | | | | | | | | | | |
|
Series A preferred stock: 4,358,597 shares authorized; 3,661,083 shares issued and outstanding at December 31, 2025 (Liquidation value of $15.3 million at December 31, 2025)
|
| | | | 19,013,673 | | | | | | — | | |
| Commitments and contingencies (Note 7) | | | | | | | | | | | | | |
| Shareholders’ deficit | | | | | | | | | | | | | |
|
Common stock, par value $0.00001 per share; 25,000,000 shares
authorized; 1,410,975 shares issued and 911,255 and 558,511 outstanding at December 31, 2025 and 2024, respectively |
| | | | 10 | | | | | | 6 | | |
|
Additional paid-in capital
|
| | | | 663,514 | | | | | | 1,207 | | |
|
Accumulated other comprehensive loss
|
| | | | (4,900) | | | | | | (609) | | |
|
Accumulated deficit
|
| | | | (10,599,083) | | | | | | (2,069,820) | | |
|
Total shareholders’ deficit
|
| | | | (9,940,459) | | | | | | (2,069,216) | | |
|
Total liabilities, convertible preferred stock and shareholders’ deficit
|
| | | $ | 10,336,680 | | | | | $ | 2,147,903 | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Revenue
|
| | | $ | 309,920 | | | | | $ | 329,410 | | |
|
Cost of revenue
|
| | | | 182,163 | | | | | | 187,848 | | |
|
Gross margin
|
| | | | 127,757 | | | | | | 141,562 | | |
| Operating expenses: | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 2,665,004 | | | | | | 368,795 | | |
|
Research and development
|
| | | | 2,578,860 | | | | | | 1,011,498 | | |
|
Total operating expenses
|
| | | | 5,243,864 | | | | | | 1,380,293 | | |
|
Loss from operations
|
| | | | (5,116,107) | | | | | | (1,238,731) | | |
| Other income (expense): | | | | | | | | | | | | | |
|
Change in fair value of SAFE liability
|
| | | | (3,493,431) | | | | | | (829,700) | | |
|
Other income
|
| | | | 80,275 | | | | | | 524 | | |
|
Loss before income taxes
|
| | | | (8,529,263) | | | | | | (2,067,907) | | |
|
Income tax expense
|
| | | | — | | | | | | (1,735) | | |
|
Net loss
|
| | | $ | (8,529,263) | | | | | $ | (2,069,642) | | |
|
Net loss per share of common stock, basic and diluted
|
| | | $ | (2.46) | | | | | $ | (2.68) | | |
|
Weighted-average shares of common stock outstanding, basic and diluted
|
| | | | 3,461,565 | | | | | | 772,351 | | |
| Comprehensive loss: | | | | | | | | | | | | | |
|
Foreign currency translation adjustments
|
| | | | (4,291) | | | | | | (609) | | |
|
Total comprehensive loss
|
| | | $ | (8,533,554) | | | | | $ | (2,070,251) | | |
SHAREHOLDERS’ DEFICIT
| | | |
Series A
Convertible Preferred Stock |
| | |
Common Stock
|
| |
Additional
Paid In Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
|
| ||||||||||||||||||||||||||||||
| | | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
|
Balance at January 1, 2024
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (178) | | | | | | (178) | | |
|
Contributions from owners
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,213 | | | | | | | | | | | | | | | | | | 1,213 | | |
|
Issuance of common stock on vesting of restricted stock
awards |
| | | | | | | | | | | | | | | | | 558,511 | | | | | | 6 | | | | | | (6) | | | | | | | | | | | | | | | | | | | | |
|
Foreign currency translation adjustments
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (609) | | | | | | | | | | | | (609) | | |
|
Net loss
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (2,069,642) | | | | | | (2,069,642) | | |
|
Balance at December 31, 2024
|
| | | | | | | | | | | | | | | | | 558,511 | | | | | | 6 | | | | | | 1,207 | | | | | | (609) | | | | | | (2,069,820) | | | | | | (2,069,216) | | |
|
Sale of Series A convertible preferred stock and common stock warrants, net of issuance costs
|
| | | | 1,933,605 | | | | | | 11,525,242 | | | | | | | | | | | | | | | | | | | 467,568 | | | | | | | | | | | | | | | | | | 467,568 | | |
|
Conversion of SAFEs into Series A convertible preferred stock
|
| | | | 1,727,478 | | | | | | 7,488,431 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Issuance of common stock on vesting of restricted stock
awards |
| | | | | | | | | | | | | | | | | 352,744 | | | | | | 4 | | | | | | (4) | | | | | | | | | | | | | | | | | | | | |
|
Share-based compensation
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 194,743 | | | | | | | | | | | | | | | | | | 194,743 | | |
|
Foreign currency translation adjustments
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (4,291) | | | | | | | | | | | | (4,291) | | |
|
Net loss
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (8,529,263) | | | | | | (8,529,263) | | |
|
Balance at December 31, 2025
|
| | | | 3,661,083 | | | | | $ | 19,013,673 | | | | | | | 911,255 | | | | | $ | 10 | | | | | $ | 663,514 | | | | | $ | (4,900) | | | | | $ | (10,599,083) | | | | | $ | (9,940,459) | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
| Operating activities: | | | | | | | | | | | | | |
|
Net loss
|
| | | $ | (8,529,263) | | | | | $ | (2,069,642) | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
|
Depreciation expense
|
| | | | 23,460 | | | | | | 3,503 | | |
|
Amortization of ROU asset
|
| | | | 15,566 | | | | | | — | | |
|
Change in fair value of SAFE liability
|
| | | | 3,493,431 | | | | | | 829,700 | | |
|
Share-based compensation expense
|
| | | | 194,743 | | | | | | — | | |
|
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
|
Unbilled revenue
|
| | | | 12,342 | | | | | | (12,342) | | |
|
Prepaid expenses and other current assets
|
| | | | (65,953) | | | | | | (49,956) | | |
|
Other assets
|
| | | | (106,935) | | | | | | — | | |
|
Accounts payable
|
| | | | 222,258 | | | | | | 983 | | |
|
Accrued expenses and other liabilities
|
| | | | (49,843) | | | | | | 203,628 | | |
|
Grant advance
|
| | | | 144,000 | | | | | | 48,000 | | |
|
Deferred revenue
|
| | | | 23,617 | | | | | | — | | |
|
Operating lease liability
|
| | | | 226 | | | | | | — | | |
|
Net cash used in operating activities
|
| | | | (4,622,351) | | | | | | (1,046,126) | | |
| Investing activities: | | | | | | | | | | | | | |
|
Purchase of property and equipment
|
| | | | (246,993) | | | | | | (8,956) | | |
|
Cash used in investing activities
|
| | | | (246,993) | | | | | | (8,956) | | |
| Financing activities: | | | | | | | | | | | | | |
|
Proceeds from issuance of SAFE liability
|
| | | | 30,000 | | | | | | 3,010,300 | | |
|
Proceeds from sale of convertible preferred stock and common stock warrants
|
| | | | 12,125,830 | | | | | | — | | |
|
Payment of financing costs
|
| | | | (77,739) | | | | | | 1,213 | | |
|
Cash provided by financing activities
|
| | | | 12,078,091 | | | | | | 3,011,513 | | |
|
Effect of exchange rates on cash and cash equivalents
|
| | | | (6,267) | | | | | | (167) | | |
|
Net increase in cash and cash equivalents
|
| | | | 7,202,480 | | | | | | 1,956,264 | | |
|
Cash and cash equivalents at the beginning of the period
|
| | | | 2,081,086 | | | | | | 124,822 | | |
|
Cash and cash equivalents at the end of the period
|
| | | $ | 9,283,566 | | | | | $ | 2,081,086 | | |
| Supplemental non-cash investing and financing activities: | | | | | | | | | | | | | |
|
Right-of-use assets obtained in exchange for operating lease obligations
|
| | | $ | 146,750 | | | | | $ | — | | |
|
Deferred offering costs in accounts payable and accrued expenses
|
| | | $ | 461,000 | | | | | $ | — | | |
|
Financing costs in accrued expenses
|
| | | $ | 66,000 | | | | | $ | — | | |
|
Issuance of preferred stock upon conversion of SAFEs
|
| | | $ | 7,488,431 | | | | | $ | — | | |
| | | |
December 31, 2024
|
| |||||||||||||||||||||
| | | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total Fair Value
|
| ||||||||||||
| Liabilities: | | | | | | | | | | | | | | | | | | | | | | | | | |
|
SAFE Liabilities
|
| | | $ | — | | | | | $ | — | | | | | $ | 3,965,000 | | | | | $ | 3,965,000 | | |
|
Total liabilities
|
| | | $ | — | | | | | $ | — | | | | | $ | 3,965,000 | | | | | $ | 3,965,000 | | |
| | | |
SAFE
Liability |
| |||
|
Balance at January 1, 2024
|
| | | $ | 125,000 | | |
|
Additions
|
| | | | 3,010,300 | | |
|
Change in fair value
|
| | | | 829,700 | | |
|
Balance at December 31, 2024
|
| | | | 3,965,000 | | |
|
Additions
|
| | | | 30,000 | | |
|
Change in fair value
|
| | | | 3,493,431 | | |
|
Conversion into convertible preferred stock
|
| | | | (7,488,431) | | |
|
Balance at December 31, 2025
|
| | | $ | — | | |
| |
Multiple scenarios expected term (in years)
|
| | | | 2.80 | | |
| |
Probability of initial public offering
|
| | | | 40% | | |
| |
Probability of stay private
|
| | | | 60% | | |
| |
Equity volatility
|
| | | | 59% | | |
| |
Risk-free rate
|
| | | | 3.5% | | |
| |
Discount rate
|
| | | | 14.1% | | |
| |
Multiple scenarios expected term (in years)
|
| | | | 1.00 | | |
| |
Probability of equity financing
|
| | | | 65% | | |
| |
Probability of liquidity event
|
| | | | 30% | | |
| |
Probability of event of default
|
| | | | 50% | | |
| | | |
December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Consulting and professional fees
|
| | | $ | 635,678 | | | | | $ | 184,252 | | |
|
Compensation
|
| | | | 13,272 | | | | | | — | | |
|
Research and development
|
| | | | — | | | | | | 11,981 | | |
|
Other
|
| | | | 31,832 | | | | | | 7,372 | | |
| | | | | $ | 680,782 | | | | | $ | 203,605 | | |
| |
2026
|
| | | $ | 75,594 | | |
| |
2027
|
| | | | 77,860 | | |
| |
Total lease payments
|
| | | | 153,454 | | |
| |
Less: present value adjustment
|
| | | | 6,478 | | |
| |
Total lease liabilities
|
| | | $ | 146,976 | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Performance obligations satisfied at point in time
|
| | | $ | 176,230 | | | | | $ | 267,945 | | |
|
Performance obligations satisfied over time
|
| | | | 133,690 | | | | | | 61,465 | | |
|
Total
|
| | | $ | 309,920 | | | | | $ | 329,410 | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Balance, beginning of year
|
| | | $ | — | | | | | $ | — | | |
|
Deferral of revenue
|
| | | | 333,192 | | | | | | 329,410 | | |
|
Recognition of unearned revenue
|
| | | | (309,920) | | | | | | (329,410) | | |
|
Balance, end of year
|
| | | $ | 23,272 | | | | | $ | — | | |
| |
Stock price per share
|
| | | $ | 1.68 | | |
| |
Term (years)
|
| | | | 1.50 | | |
| |
Volatility
|
| | | | 59.0% | | |
| |
Dividend yield
|
| | | | 0.0% | | |
| |
Risk-free interest rate
|
| | | | 3.5% | | |
| | | |
Authorized
Shares |
| |
Issued and
Outstanding Shares |
| |
Liquidation
Value |
| |
Carrying
Value |
| ||||||||||||
|
Series A-1
|
| | | | 2,631,119 | | | | | | 1,933,605 | | | | | $ | 12,125,830 | | | | | $ | 11,525,242 | | |
|
Series A-2
|
| | | | 223,336 | | | | | | 223,336 | | | | | | 125,000 | | | | | | 844,210 | | |
|
Series A-3
|
| | | | 223,246 | | | | | | 223,246 | | | | | | 209,999 | | | | | | 880,929 | | |
|
Series A-4
|
| | | | 1,262,162 | | | | | | 1,262,162 | | | | | | 2,770,293 | | | | | | 5,670,894 | | |
|
Series A-5
|
| | | | 12,756 | | | | | | 12,756 | | | | | | 29,998 | | | | | | 58,180 | | |
|
Series A-6
|
| | | | 5,978 | | | | | | 5,978 | | | | | | 29,991 | | | | | | 34,218 | | |
|
Total
|
| | | | 4,358,597 | | | | | | 3,661,083 | | | | | $ | 15,291,111 | | | | | $ | 19,013,673 | | |
| | | |
Number of
Shares |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term (years) |
| |||||||||
|
Outstanding at January 1, 2024
|
| | | | 5,643,900 | | | | | $ | 0.00 | | | | | | | | |
|
Granted
|
| | | | 752,520 | | | | | $ | 0.00 | | | | | | | | |
|
Outstanding at December 31, 2024
|
| | | | 6,396,420 | | | | | $ | 0.00 | | | | | | | | |
|
Granted
|
| | | | 2,686,075 | | | | | $ | 3.09 | | | | | | | | |
|
Forfeited
|
| | | | (9,521) | | | | | $ | 0.67 | | | | | | | | |
|
Outstanding at December 31, 2025
|
| | | | 9,072,974 | | | | | $ | 0.91 | | | | | | 9.05 | | |
|
Vested and Exercisable at December 31, 2025
|
| | | | 3,831,951 | | | | | $ | 0.16 | | | | | | 7.87 | | |
| |
Expected volatility
|
| | | | 50.3% | | |
| |
Risk-free interest rate
|
| | | | 3.7% | | |
| |
Expected term (in years)
|
| | | | 5.9 | | |
| |
Expected dividend yield
|
| | | | 0.0% | | |
| | | | | | |
Weighted Average
Grant Date Fair Value |
| ||||||
|
Unvested at January 1, 2024
|
| | | | 1,410,975 | | | | | $ | 0.00 | | |
|
Vested
|
| | | | (558,511) | | | | | $ | 0.00 | | |
|
Unvested at December 31, 2024
|
| | | | 852,464 | | | | | $ | 0.00 | | |
|
Vested
|
| | | | (352,744) | | | | | $ | 0.00 | | |
|
Unvested at December 31, 2025
|
| | | | 499,720 | | | | | $ | 0.00 | | |
| | | |
December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Convertible preferred stock
|
| | | | 6,887,620 | | | | | | — | | |
|
Common stock warrants
|
| | | | 2,999,950 | | | | | | — | | |
|
Unvested restricted stock awards
|
| | | | 499,720 | | | | | | 852,464 | | |
|
Stock options
|
| | | | 5,474,986 | | | | | | 4,397,540 | | |
| | | | | | 15,862,276 | | | | | | 5,250,004 | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
United States
|
| | | $ | (7,432,105) | | | | | $ | (2,096,105) | | |
|
Ukraine
|
| | | | (298,812) | | | | | | 28,198 | | |
|
Estonia
|
| | | | (798,346) | | | | | | — | | |
| | | | | $ | (8,529,263) | | | | | $ | (2,067,907) | | |
| | | |
Years Ended December 31,
|
| |||||||||||||||||||||
| | | |
2025
|
| |
2024
|
| ||||||||||||||||||
|
U.S. Statutory Tax Rate
|
| | | | (1,791,145) | | | | | | 21.0% | | | | | | (434,260) | | | | | | 21.0% | | |
|
State and Local Income Taxes, Net of Federal Income Tax Effect*
|
| | | | (259,769) | | | | | | 3.0% | | | | | | (86,655) | | | | | | 4.2% | | |
|
Foreign Tax Effects
|
| | | | — | | | | | | | | | | | | — | | | | | | | | |
|
Ukraine
|
| | | | — | | | | | | | | | | | | — | | | | | | | | |
|
Statutory tax rate difference between Ukraine and United States
|
| | | | 8,964 | | | | | | -0.1% | | | | | | (289) | | | | | | -0.1% | | |
|
Change in valuation allowance
|
| | | | 53,786 | | | | | | -0.6% | | | | | | — | | | | | | 0.0% | | |
|
Other
|
| | | | — | | | | | | 0.0% | | | | | | — | | | | | | 0.0% | | |
|
Estonia
|
| | | | — | | | | | | 0.0% | | | | | | — | | | | | | 0.0% | | |
|
Statutory tax rate difference between Estonia and United States
|
| | | | (7,983) | | | | | | 0.1% | | | | | | — | | | | | | 0.0% | | |
|
Change in valuation allowance
|
| | | | 175,636 | | | | | | -2.1% | | | | | | — | | | | | | 0.0% | | |
|
Other
|
| | | | — | | | | | | 0.0% | | | | | | — | | | | | | 0.0% | | |
|
Effect of Changes in Tax Laws or Rates Enacted in the Current
Period |
| | | | — | | | | | | 0.0% | | | | | | — | | | | | | 0.0% | | |
|
Effect of Cross-Border Tax Laws
|
| | | | — | | | | | | 0.0% | | | | | | — | | | | | | 0.0% | | |
|
U.S. Federal R&D Tax Credits
|
| | | | (118,280) | | | | | | 1.4% | | | | | | (6,606) | | | | | | 0.3% | | |
|
Change in Valuation Allowances
|
| | | | 1,171,755 | | | | | | -13.7% | | | | | | 358,029 | | | | | | -17.1% | | |
|
Nontaxable or Nondeductible Items
|
| | | | 33,416 | | | | | | -0.4% | | | | | | (2,721) | | | | | | 0.1% | | |
|
Changes in Unrecognized Tax Benefits
|
| | | | — | | | | | | 0.0% | | | | | | — | | | | | | 0.0% | | |
|
Other Adjustments
|
| | | | — | | | | | | | | | | | | — | | | | | | | | |
|
Change in FV of SAFE Liability
|
| | | | 733,620 | | | | | | -8.6% | | | | | | 174,237 | | | | | | -8.4% | | |
|
Actual income tax benefit effective tax rate
|
| | | | — | | | | | | 0.0% | | | | | | 1,735 | | | | | | 0.0% | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
| Deferred tax assets: | | | | | | | | | | | | | |
|
Net operating loss carryforwards
|
| | | $ | 1,355,370 | | | | | $ | 261,570 | | |
|
Accruals and other
|
| | | | 246,023 | | | | | | 64,374 | | |
|
Capitalized research and development expenditures
|
| | | | 19,853 | | | | | | 25,528 | | |
|
Research and development tax credits
|
| | | | 124,886 | | | | | | 6,606 | | |
|
Lease liabilities
|
| | | | 40,967 | | | | | | — | | |
|
Share-based compensation
|
| | | | 11,706 | | | | | | — | | |
|
Total deferred tax assets
|
| | | | 1,798,804 | | | | | | 358,078 | | |
|
Less: valuation allowance
|
| | | | (1,759,255) | | | | | | (358,078) | | |
|
Deferred tax asset, net of valuation allowance
|
| | | $ | 39,548 | | | | | $ | — | | |
| Deferred tax liabilities: | | | | | | | | | | | | | |
|
Depreciation and amortization
|
| | | | (2,983) | | | | | | — | | |
|
Right-of-use assets
|
| | | | (36,565) | | | | | | — | | |
|
Total deferred tax liabilities
|
| | | | (39,548) | | | | | | — | | |
|
Net deferred tax assets
|
| | | $ | — | | | | | $ | — | | |
| | | |
Years Ended December 31,
|
| |||||||||
| | | |
2025
|
| |
2024
|
| ||||||
|
Revenue
|
| | | $ | 309,920 | | | | | $ | 329,410 | | |
|
Cost of revenue
|
| | | | 182,163 | | | | | | 187,848 | | |
|
Gross margin
|
| | | | 127,757 | | | | | | 141,562 | | |
| Operating expenses: | | | | | | | | | | | | | |
|
Professional fees and consultants
|
| | | | 4,237,050 | | | | | | 1,097,942 | | |
|
Research and development
|
| | | | 276,375 | | | | | | 118,036 | | |
|
General and administrative
|
| | | | 699,576 | | | | | | 164,109 | | |
|
Sales and marketing
|
| | | | 30,863 | | | | | | 206 | | |
|
Total operating expenses
|
| | | | 5,243,864 | | | | | | 1,380,293 | | |
|
Change in fair value of SAFE liability
|
| | | | 3,493,431 | | | | | | 829,700 | | |
|
Other income
|
| | | | (80,275) | | | | | | (524) | | |
|
Loss before income taxes
|
| | | | (8,529,263) | | | | | | (2,067,907) | | |
|
Income tax expense
|
| | | | — | | | | | | (1,735) | | |
|
Segment net loss
|
| | | $ | (8,529,263) | | | | | $ | (2,069,642) | | |
| |
Series A-1:
|
| | | | 3.3334 | | |
| |
Series A-2:
|
| | | | 0.2975 | | |
| |
Series A-3:
|
| | | | 0.5000 | | |
| |
Series A-4:
|
| | | | 1.1667 | | |
| |
Series A-5:
|
| | | | 1.2499 | | |
| |
Series A-6:
|
| | | | 2.6663 | | |
(Unaudited)
| | | |
March 31,
2026 |
| |
December 31,
2025 |
| ||||||
| Assets | | | | | | | | | | | | | |
| Current assets: | | | | | | | | | | | | | |
|
Cash and cash equivalents
|
| | | $ | 23,472,156 | | | | | $ | 9,283,566 | | |
|
Prepaid expenses and other current assets
|
| | | | 795,309 | | | | | | 115,473 | | |
|
Total current assets
|
| | | | 24,267,465 | | | | | | 9,399,039 | | |
|
Property and equipment, net
|
| | | | 309,457 | | | | | | 227,908 | | |
|
Operating lease right-of-use asset
|
| | | | 115,494 | | | | | | 131,184 | | |
|
Deferred offering costs
|
| | | | — | | | | | | 471,719 | | |
|
Other assets
|
| | | | 234,694 | | | | | | 106,830 | | |
|
Total assets
|
| | | $ | 24,927,110 | | | | | $ | 10,336,680 | | |
| Liabilities, convertible preferred stock and shareholders’ deficit | | | | | | | | | | | | | |
| Current liabilities: | | | | | | | | | | | | | |
|
Accounts payable
|
| | | $ | 344,253 | | | | | $ | 223,236 | | |
|
Accrued expenses and other current liabilities
|
| | | | 747,538 | | | | | | 680,782 | | |
|
Grant advance
|
| | | | 182,667 | | | | | | 189,200 | | |
|
Deferred revenue
|
| | | | 2,371 | | | | | | 23,272 | | |
|
Operating lease liability – current
|
| | | | 72,070 | | | | | | 70,703 | | |
|
Total current liabilities
|
| | | | 1,348,899 | | | | | | 1,187,193 | | |
|
Operating lease liability – non-current
|
| | | | 57,620 | | | | | | 76,273 | | |
|
Total liabilities
|
| | | | 1,406,519 | | | | | | 1,263,466 | | |
| Convertible preferred stock, par value $0.00001 per share: | | | | | | | | | | | | | |
|
Series A preferred stock: 10,000,000 shares authorized as of March 31,
2026 and 4,358,597 shares authorized as of December 31, 2025; no shares issued and outstanding as of March 31, 2026 and 3,661,083 shares issued and outstanding as of December 31, 2025 |
| | | | — | | | | | | 19,013,673 | | |
| Commitments and contingencies (Note 5) | | | | | | | | | | | | | |
| Shareholders’ equity (deficit) | | | | | | | | | | | | | |
|
Common stock, $0.00001 par value; 200,000,000 and 25,000,000 shares
authorized as of March 31, 2026 and December 31, 2025, respectively; 11,210,256 and 1,410,975 shares issued as of March 31, 2026 and December 31, 2025, respectively; and 10,798,722 and 911,255 shares outstanding as of March 31, 2026 and December 31, 2025, respectively |
| | | | 110 | | | | | | 10 | | |
|
Additional paid-in capital
|
| | | | 38,606,840 | | | | | | 663,514 | | |
|
Accumulated other comprehensive loss
|
| | | | (28,441) | | | | | | (4,900) | | |
|
Accumulated deficit
|
| | | | (15,057,918) | | | | | | (10,599,083) | | |
|
Total shareholders’ equity (deficit)
|
| | | | 23,520,591 | | | | | | (9,940,459) | | |
|
Total liabilities, convertible preferred stock and shareholders’ equity (deficit)
|
| | | $ | 24,927,110 | | | | | $ | 10,336,680 | | |
(Unaudited)
| | | |
Three Months Ended March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
|
Revenue
|
| | | $ | 20,325 | | | | | $ | 110,704 | | |
|
Cost of revenue
|
| | | | 39,924 | | | | | | 45,542 | | |
|
Gross margin
|
| | | | (19,599) | | | | | | 65,162 | | |
| Operating expenses: | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 3,004,879 | | | | | | 255,281 | | |
|
Research and development
|
| | | | 1,486,082 | | | | | | 522,198 | | |
|
Total operating expenses
|
| | | | 4,490,961 | | | | | | 777,479 | | |
|
Loss from operations
|
| | | | (4,510,560) | | | | | | (712,317) | | |
| Other income: | | | | | | | | | | | | | |
|
Other income
|
| | | | 51,725 | | | | | | 18,340 | | |
|
Loss before income taxes
|
| | | | (4,458,835) | | | | | | (693,977) | | |
|
Income tax expense
|
| | | | — | | | | | | — | | |
|
Net loss
|
| | | $ | (4,458,835) | | | | | $ | (693,977) | | |
|
Net loss per share of common stock, basic and diluted
|
| | | $ | (0.28) | | | | | $ | (0.25) | | |
|
Weighted-average shares of common stock outstanding, basic and diluted
|
| | | | 16,064,920 | | | | | | 2,725,467 | | |
| Comprehensive loss: | | | | | | | | | | | | | |
|
Foreign currency translation adjustments
|
| | | | (23,541) | | | | | | 266 | | |
|
Total comprehensive loss
|
| | | $ | (4,482,376) | | | | | $ | (693,711) | | |
STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
| | | |
Series A
Convertible Preferred Stock |
| | |
Common Stock
|
| |
Additional
Paid-in- Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
|
| ||||||||||||||||||||||||||||||
| | | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
|
Balance at December 31, 2025
|
| | | | 3,661,083 | | | | | $ | 19,013,673 | | | | | | | 911,255 | | | | | $ | 10 | | | | | $ | 663,514 | | | | | $ | (4,900) | | | | | $ | (10,599,083) | | | | | $ | (9,940,459) | | |
|
Sale of Series A-1 convertible preferred stock
|
| | | | 558,116 | | | | | | 3,472,095 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Issuance of common stock and pre-funded warrants for conversion of Series A convertible preferred stock
|
| | | | (4,219,199) | | | | | | (22,485,768) | | | | | | | 6,137,634 | | | | | | 62 | | | | | | 22,485,706 | | | | | | — | | | | | | — | | | | | | 22,485,768 | | |
|
Issuance of common stock under
initial public offering, net of underwriters discounts |
| | | | — | | | | | | — | | | | | | | 3,450,000 | | | | | | 35 | | | | | | 16,014,965 | | | | | | — | | | | | | — | | | | | | 16,015,000 | | |
|
Reclassification of deferred financing costs to additional paid-in capital upon consummation of public offering and sale of Series A convertible preferred stock
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | (839,222) | | | | | | — | | | | | | — | | | | | | (839,222) | | |
|
Issuance of common stock upon
exercise of stock options |
| | | | — | | | | | | — | | | | | | | 211,647 | | | | | | 2 | | | | | | (2) | | | | | | — | | | | | | — | | | | | | — | | |
|
Issuance of common stock on vesting of restricted stock awards
|
| | | | — | | | | | | — | | | | | | | 88,186 | | | | | | 1 | | | | | | (1) | | | | | | — | | | | | | — | | | | | | — | | |
|
Share-based compensation
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 281,880 | | | | | | — | | | | | | — | | | | | | 281,880 | | |
|
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (23,541) | | | | | | — | | | | | | (23,541) | | |
|
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (4,458,835) | | | | | | (4,458,835) | | |
|
Balance at March 31, 2026
|
| | |
|
—
|
| | | | $ | — | | | | | | | 10,798,722 | | | | | $ | 110 | | | | | $ | 38,606,840 | | | | | $ | (28,441) | | | | | $ | (15,057,918) | | | | | $ | 23,520,591 | | |
| | | |
Common Stock
|
| |
Additional
Paid-in- Capital |
| |
Accumulated
Other Comprehensive Loss |
| |
Accumulated
Deficit |
| |
Total
|
| |||||||||||||||||||||
| | | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
|
Balance at December 31, 2024
|
| | | | 558,511 | | | | | $ | 6 | | | | | $ | 1,207 | | | | | $ | (609) | | | | | $ | (2,069,820) | | | | | $ | (2,069,216) | | |
|
Issuance of common stock on vesting of restricted stock
awards |
| | | | 88,186 | | | | | | 1 | | | | | | (1) | | | | | | — | | | | | | — | | | | | | — | | |
|
Share-based compensation
|
| | |
|
—
|
| | | |
|
—
|
| | | | | 10,233 | | | | | | — | | | | | | — | | | | | | 10,233 | | |
|
Foreign currency translation adjustments
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | 266 | | | | | | — | | | | | | 266 | | |
|
Net loss
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | — | | | | | | (693,977) | | | | | | (693,977) | | |
|
Balance at March 31, 2025
|
| | | | 646,697 | | | | | $ | 7 | | | | | $ | 11,439 | | | | | $ | (343) | | | | | $ | (2,763,797) | | | | | $ | (2,752,694) | | |
(Unaudited)
| | | |
Three Months Ended March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
| Operating activities: | | | | | | | | | | | | | |
|
Net loss
|
| | | $ | (4,458,835) | | | | | $ | (693,977) | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
|
Depreciation expense
|
| | | | 38,237 | | | | | | — | | |
|
Amortization of ROU asset
|
| | | | 15,690 | | | | | | — | | |
|
Share-based compensation expense
|
| | | | 281,880 | | | | | | 10,233 | | |
|
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
|
Unbilled revenue
|
| | | | — | | | | | | (34,269) | | |
|
Prepaid expenses and other current assets
|
| | | | (220,046) | | | | | | (23,036) | | |
|
Other assets
|
| | | | (128,108) | | | | | | (2,945) | | |
|
Accounts payable
|
| | | | 98,580 | | | | | | 40,890 | | |
|
Accrued expenses and other liabilities
|
| | | | 133,172 | | | | | | 6,570 | | |
|
Deferred revenue
|
| | | | (20,332) | | | | | | 14,737 | | |
|
Operating lease liability
|
| | | | (17,286) | | | | | | — | | |
|
Net cash used in operating activities
|
| | | | (4,277,048) | | | | | | (681,797) | | |
| Investing activities: | | | | | | | | | | | | | |
|
Purchase of property and equipment
|
| | | | (124,331) | | | | | | — | | |
|
Cash used in investing activities
|
| | | | (124,331) | | | | | | — | | |
| Financing activities: | | | | | | | | | | | | | |
|
Proceeds from initial public offering, net of underwriting discounts
|
| | | | 16,015,000 | | | | | | — | | |
|
Proceeds from sale of Series A-1 convertible preferred stock
|
| | | | 3,472,095 | | | | | | — | | |
|
Payment of financing costs
|
| | | | (870,790) | | | | | | — | | |
|
Cash provided by financing activities
|
| | | | 18,616,305 | | | | | | — | | |
|
Effect of exchange rates on cash and cash equivalents
|
| | | | (26,336) | | | | | | (1,785) | | |
|
Net increase (decrease) in cash and cash equivalents
|
| | | | 14,188,590 | | | | | | (683,582) | | |
|
Cash and cash equivalents at the beginning of the period
|
| | | | 9,283,566 | | | | | | 2,081,086 | | |
|
Cash and cash equivalents at the end of the period
|
| | | $ | 23,472,156 | | | | | $ | 1,397,504 | | |
| Supplemental non-cash investing and financing activities: | | | | | | | | | | | | | |
|
Conversion of Series A convertible preferred stock into common stock and pre-funded warrants
|
| | | $ | 22,485,768 | | | | | $ | — | | |
|
Financing costs included in accounts payable
|
| | | $ | 22,500 | | | | | $ | — | | |
| | | |
March 31,
2026 |
| |
December 31,
2025 |
| ||||||
|
Liability under D&O insurance premium financing
|
| | | $ | 417,774 | | | | | $ | — | | |
|
Consulting and professional fees
|
| | | | 297,604 | | | | | | 635,678 | | |
|
Compensation
|
| | | | 690 | | | | | | 13,272 | | |
|
Other
|
| | | | 31,470 | | | | | | 31,832 | | |
| | | | | $ | 747,538 | | | | | $ | 680,782 | | |
| | | |
Operating
leases |
| |||
|
2026
|
| | | $ | 56,790 | | |
|
2027
|
| | | | 77,860 | | |
|
Total lease payments
|
| | | | 134,650 | | |
|
Less: present value adjustment
|
| | | | (4,960) | | |
|
Total lease liabilities
|
| | | $ | 129,690 | | |
| | | |
Three Months Ended March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
|
Performance obligations satisfied at point in time
|
| | | $ | — | | | | | $ | 78,249 | | |
|
Performance obligations satisfied over time
|
| | | | 20,325 | | | | | | 32,455 | | |
|
Total
|
| | | $ | 20,325 | | | | | $ | 110,704 | | |
| | | |
Three Months Ended March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
|
Balance, beginning of period
|
| | | $ | 23,272 | | | | | $ | — | | |
|
Deferral of revenue
|
| | | | (576) | | | | | | 110,704 | | |
|
Recognition of unearned revenue
|
| | | | (20,325) | | | | | | (110,704) | | |
|
Balance, end of period
|
| | | $ | 2,371 | | | | | $ | — | | |
| | | |
Number of
Shares |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term (years) |
| |||||||||
|
Outstanding at December 31, 2025
|
| | | | 9,072,974 | | | | | $ | 0.91 | | | | | | — | | |
|
Granted
|
| | | | 1,110,416 | | | | | | 4.54 | | | | | | — | | |
|
Exercised
|
| | | | (211,647) | | | | | | — | | | | | | — | | |
| | | |
Number of
Shares |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term (years) |
| |||||||||
|
Forfeited
|
| | | | (164,613) | | | | | | — | | | | | | — | | |
|
Outstanding at March 31, 2026
|
| | | | 9,807,130 | | | | | $ | 1.36 | | | | | | 8.33 | | |
|
Vested and Exercisable at March 31, 2026
|
| | | | 4,270,235 | | | | | $ | 0.17 | | | | | | 7.64 | | |
| | |||||||||||||||||||
| | | |
BSM
Assumptions for Grants in 2026 |
| |||
|
Expected volatility
|
| | | | 51.5% | | |
|
Risk-free interest rate
|
| | | | 3.9% | | |
|
Expected term (in years)
|
| | | | 6.0 | | |
|
Expected dividend yield
|
| | | | 0.0% | | |
| | | |
Weighted Average Grant
Date Fair Value |
| |||||||||
|
Unvested at December 31, 2025
|
| | | | 499,720 | | | | | $ | 0.00 | | |
|
Vested
|
| | | | (88,186) | | | | | | — | | |
|
Unvested at March 31, 2026
|
| | | | 411,534 | | | | | $ | 0.00 | | |
| | | |
March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
|
Common stock warrants
|
| | | | 2,999,950 | | | | | | — | | |
|
Unvested restricted stock awards
|
| | | | 411,534 | | | | | | 764,278 | | |
|
Stock options
|
| | | | 2,398,660 | | | | | | 4,549,844 | | |
| | | | | | 5,810,144 | | | | | | 5,314,122 | | |
| | | |
Three Months Ended March 31,
|
| |||||||||
| | | |
2026
|
| |
2025
|
| ||||||
|
Revenue
|
| | | $ | 20,325 | | | | | $ | 110,704 | | |
|
Cost of revenue
|
| | | | 39,924 | | | | | | 45,542 | | |
|
Gross margin
|
| | | | (19,599) | | | | | | 65,162 | | |
| Operating expenses: | | | | | | | | | | | | | |
|
Selling, general and administrative
|
| | | | 3,004,879 | | | | | | 255,281 | | |
|
Research and development
|
| | | | 1,486,082 | | | | | | 522,198 | | |
|
Total operating expenses
|
| | | | 4,490,961 | | | | | | 777,479 | | |
|
Other income
|
| | | | 51,725 | | | | | | 18,340 | | |
|
Loss before income taxes
|
| | | | (4,458,835) | | | | | | (693,977) | | |
|
Income tax expense
|
| | | | — | | | | | | — | | |
|
Segment net loss
|
| | | $ | (4,458,835) | | | | | $ | (693,977) | | |